Abstract
Our pilot study suggests that the combination of fractionated TLI and CY is well tolerated by pancytopenic patients and permits rapid marrow engraftment. Whether TLI reduces the incidence and/or the severity of GVHD in bone marrow transplantation in man cannot be determined on the basis of the limited experience described here. Nevertheless, the results have produced sufficient enthusiasm for further clinical trials in nonmalignant hematologic disorders.
Original language | English |
---|---|
Pages (from-to) | 668-670 |
Number of pages | 3 |
Journal | Transplantation Proceedings |
Volume | 15 |
Issue number | 1 |
State | Published - 1983 |
Bibliographical note
Export Date: 03 October 2022; Cited By: 13; CODEN: TRPPAKeywords
- cyclophosphamide
- HLA antigen
- methotrexate
- aplastic anemia
- blood and hemopoietic system
- bone marrow transplantation
- case report
- drug therapy
- human
- immunosuppressive treatment
- intravenous drug administration
- lymph node irradiation
- lymphatic system
- sibling
- therapy